This Web Site is committed to the memory of Janis Morrow.
Hepatitis C Research
News & Articles
2004
2003 Research News and Articles
December 2004
Hepatitis C Infection and the Increasing Incidence of Hepatocellular Carcinoma
Epoetin Alfa Improves Quality of Life in Anemic HCV Patients Receiving Combination Therapy
Peginterferon Alfa-2a (Pegasys) and Ribavirin in Patients with Chronic HCV and Normal ALT Levels
Only One Therapy Option Is FDA-approved for Treatment of Hepatitis C Infection in Children
Pegylated interferon-alfa-2b + ribavirin therapy for recurrent hep C virus
Pegasys/RBV Improves Fibrosis in Responders, relapsers & Nonresponders with Advanced Fibrosis
November 2004
The news this month is on research :
If you are on treatment or thinking about treatment this is your place for research.
Our message boards have the latest reports coming out of the AASLD . Here you can also comment on the research.
Oct 29- Nov 1 2004 Research Conferences
HIVandHepatitis.com and HCVAdvocate.org are the best sites for the AASLD 2004 Research Conferences .
Clicking below will take you away from our site, click on your back button to return to Janis and Friends
From HIVandHepatitis.com :
55th Annual Meeting of the American Society for the Study of Liver Diseases (55th AASLD)
October 29 - November 2, 2004, Boston, MA
From HCV Advocate :
October 2004
New Liver Rejection Treatment Approach Demonstrates Its Merit, Doctors Say
Long-Term Outcomes in HCV with SVR: cure, regression of fibrosis
What's Worse Than Hep as Cancer Cause? Docs Have Theory
World Hepatitis C Awareness Day tomorrow
Fatty Liver Accelerates Fibrosis: diabetes, mitochondrial dyfunction, obesity associated
Interferon and cirrhosis tied to liver failure in HIV/HCV coinfection
Retreatment of Patients Who Do Not Respond to Initial Therapy for Chronic Hepatitis C
September 2004
Natural killer cell interactions govern immunity to hepatitis C virus
Natural history of initially mild chronic hepatitis C
Spontaneous hepatitis C virus clearance occurs in up to 42% recently infected, HIV-negative IDUs
Roche Gets Fast-Track Status For HIV/Hepatitis C Treatment
Hepatitis C recurrence after living donor transplantation
Prospective study in 142 cases of hepatitis C virus infection.
Can You Have Multiple Genotypes?
How
Durable is the HCV Sustained Viral Response?
August 2004
Treatment of HCV infection in patients with advanced cirrhosis
Pegylated interferon can cause serious eye problems in HIV/HCV coinfected patients, says study
Significant advance in the understanding of the hepatitis C virus (HCV)
Potential Current and Future Therapeutic Options for Nonresponders to
Antiviral Therapy for Chronic HCV
Common
Heterozygous Hemochromatosis Gene Mutations Are Risk Factors for
Inflammation and Fibrosis in Chronic Hepatitis C
Is There a Correlation Between HCV Viral Load and Severity of Liver Disease?
Mt Sinai School of Medicine Press Release on APRICOT COINFECTION STUDY RESULTS
HCV Therapy Should Depend on Genotype, Doc Says
July 2004
Hepatitis C Linked To Lymphoma
Thyroid disorders in chronic hepatitis C.
New Pegasys Study data: 43% of non-responders have histological improvement
Peginterferon alfa-2b and Ribavirin for 24 Weeks Sufficient for Genotype 2 or 3 Chronic HCV
Ultrasensitive testing detects persistent HCV RNA in patients with resolved HCV infection
As Doctor Writes Prescription, Drug Company Writes a Check
Re-Examining
Questions about Hepatitis C
Racial Differences in Chronic Hepatitis C-Related Liver Inflammation and Fibrosis
June 2004
Consensus Interferon Shows Sustained Response
Keeping Transplanted Livers Healthy is a Challenge, Say Doctors
Treatment helps 26% of black Americans with chronic hepatitis C
Stem Cells Can Convert To Liver Tissue, Help Restore Damaged Organ
Pegasys- or Peg-Intron-based combination therapy? Which is better?
How Ideal Is the IDEAL Trial? Jun 04 2004
HCV Treatment for Nonresponders
Complementary and Alternative Therapies for Chronic Hepatitis C: Randomized Trial Data Review
The Case for Hepatitis C-related Arthritis
May 2004
|
Conventional (non-pegylated) Interferon +/- Ribavirin Therapy |
|
| • | Intron A and Ribavirin for the Treatment Of HCV Patients Who Failed Prior Therapy - 05/19/04 |
| • | Trend to Improved SVR among African-Americans Receiving High Dose Induction Therapy with Conventional Interferon + Ribavirin - 05/19/04 |
| • | PEG-Intron Plus Ribavirin for Retreatment of Chronic Hepatitis C 05/17/04 |
|
Cognitive behavioral therapy |
|
| • | Persistence of Improved Adherence and Quality of Life with Cognitive Behavioral Therapy in Patients Receiving PEG-Intron Plus Ribavirin - 05/19/04 |
|
Viral eradication |
|
| • | In a US Cohort the Large Majority of Individuals with Acute Hepatitis C Experience Spontaneous or Therapy-induced Viral Clearance - 05/19/04 |
|
Quality of life (QoL) |
|
| • | Persistence of Improved Adherence and Quality of Life with Cognitive Behavioral Therapy in Patients Receiving PEG-Intron Plus Ribavirin - 05/19/04 |
|
Adherence |
|
| • | Persistence of Improved Adherence and Quality of Life with Cognitive Behavioral Therapy in Patients Receiving PEG-Intron Plus Ribavirin - 05/19/04 |